Trump Orders FDA to Fast-Track Psychedelic Therapies for PTSD and Mental Health Treatment

Trump Administration Fast-Tracks Psychedelic Therapies for PTSD and Mental Health

The Trump administration has issued a sweeping executive order directing the FDA to expedite the review and approval of psychedelic therapies, including ibogaine, for the treatment of post-traumatic stress disorder (PTSD) and other serious mental health conditions. The policy aims to accelerate research funding, streamline FDA pathways, and improve patient access to experimental treatments.

The executive order explicitly prioritizes ibogaine therapy despite ongoing concerns about its safety profile and limited clinical research. This directive coincides with President Trump’s recent announcement to reclassify medical cannabis as a less dangerous drug, signaling a broader shift in federal drug policy.

Key Provisions of the Executive Order

• FDA Review Acceleration: The order instructs the FDA to expedite approval processes for high-priority psychedelic treatments, including the use of Commissioner’s National Priority Vouchers to incentivize development.
• $50 Million in Funding: The administration has allocated $50 million to support state-level research into psychedelic therapies.
• Mental Health Crisis Focus: The policy targets the high burden of suicide and serious mental illness, particularly among U.S. veterans, who face disproportionate rates of PTSD and related conditions.

Coalition Support and Public Reaction

A diverse coalition of stakeholders has praised the executive order, including psychedelic research organizations, medical professionals, veterans groups, and podcaster Joe Rogan. Supporters argue that the move builds on decades of scientific progress and could revolutionize mental health treatment.

“This is welcome news and builds upon decades of science.”

— Matthew Johnson, PhD, Professor of Psychiatry and Behavioral Sciences, Johns Hopkins University

Psychedelics in Mental Health Treatment: A Growing Field

Psychedelics, which act on the body’s serotonin system, have gained significant attention for their potential in treating a range of mental health disorders. Common examples include:

• LSD (lysergic acid diethylamide)
• Psilocybin (found in “magic mushrooms”)
• DMT (dimethyltryptamine)

Research into psychedelic therapies has evolved from the fringes of counterculture to mainstream scientific inquiry. Current studies explore their efficacy in treating conditions such as:

• Substance misuse
• Alcohol use disorder
• Depression
• Anxiety
• PTSD

Safety Concerns and Cautious Optimism

While the executive order has been widely celebrated, some experts have raised concerns about the risks of expediting FDA approval for experimental therapies. Richard Friedman, MD, a psychiatrist and director of the Psychopharmacology Clinic at Weill Cornell Medicine, emphasized the need for rigorous safety evaluations.

“It’s important to explore the use of psychedelics to treat hard-to-treat disorders like PTSD—that’s completely reasonable. What we don’t want to do is speed up the testing and evaluation of drugs if it means that we’re giving short shrift to the rigorous analysis of safety.”

— Richard Friedman, MD, Weill Cornell Medicine

Broader Implications for Drug Policy

The executive order reflects a broader trend toward reevaluating the federal stance on controlled substances. Earlier this year, Trump announced plans to reclassify medical cannabis as a less dangerous drug, further signaling a shift in drug policy priorities. The administration’s focus on psychedelics and cannabis underscores a growing recognition of their potential therapeutic benefits.

As research accelerates and policy evolves, the debate over the safety, efficacy, and accessibility of psychedelic therapies is likely to intensify. For now, the executive order marks a significant step toward addressing the nation’s mental health crisis through innovative treatment pathways.